• Home
  • About US
  • Contact Us
  • Privacy Policy
  • Terms of Use

Archives

  • November 2026
  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • July 2024
  • June 2024
  • May 2024
  • April 2024
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • March 2022
  • February 2022
  • January 2022
  • November 2019

Categories

  • Auto
  • Business
  • Climate & Earth
  • Coronavirus
  • Crypto
  • Entertainment
  • Happiness Basket
  • India
  • Learn | Unlearn | Relearn
  • Lifestyle
  • Politics
  • Research Discoveries
  • Science & Technology
  • Sports
  • Trending
  • Video
  • World
  • Home
  • About US
  • Contact Us
  • Privacy Policy
  • Terms of Use
Read Selective
  • World
  • Politics
  • India
  • Business
  • Entertainment
  • Lifestyle
  • Auto
  • Crypto
  • Coronavirus
  • Happiness Basket
  • Research Discoveries
  • India

‘AI speeding up drug design; next step is faster, cheaper medicines’: Siddhartha Mukherjee at HT Leadership Summit

  • November 15, 2026

He urged safeguards for faster trials and said India has a historic opportunity to make medicines faster, cheaper and better.

Siddhartha Mukherjee, co-founder and chief executive of the drug-discovery company Manas AI at the Hindustan Times Leadership Summit. (HT Photo)

Artificial intelligence is already cutting the time it takes to design new medicines from years to months, oncologist and author Siddhartha Mukherjee said on Saturday, but it must now make medicines faster, cheaper and better for patients if it is to prove its worth.

“The single mitigating feature of AI is its capacity to produce transformative medicine,” Mukherjee, co-founder and chief executive of the drug-discovery company Manas AI, said at the 24th edition of the Hindustan Times Leadership Summit. “Exhibit A of AI’s transformative power for human good is medicine. And if we fail in exhibit A, that creates an enormous problem for… whether we put up data centres or not, or what the value is of AI in various other industries.”

The harder part, he said, is what happens after a molecule is designed: testing it in people and getting it approved, which have barely changed. AI could speed up clinical trials too, he said, but only with safeguards, so that medicines that do not work are not released to patients.

India, he said, has a “historic opportunity” to show what AI can deliver if it reforms how new drugs are tested and approved.

To lay out his case, Mukherjee explained how arduous drug discovery can be.

Every medicine binds to a protein in the body, the way a key fits a lock, he explained. There are 10 to the power of 24 possible small-molecule keys, far too many to try one by one, so modern drug design starts with the lock: find a “keyhole” in the target protein, then build a molecule from scratch to fit it.

This is where AI comes in, he said, citing his company Manas, which combines AI, “which is a neural system”, with what it calls “medicinal intelligence”: “the rules of physics and chemistry”.

Illustrating how the technology can compress timelines for drug discovery, he cited the case of daraxonrasib, a pancreatic cancer drug. “It took a human researcher about ten years to find that keyhole,” Mukherjee said, adding: “It took our algorithm two hours to find that same keyhole.” That gain, he said, came “just from the keyhole finding module”.

Manas sends 50 to 100 compounds at a time to Chinese chemical companies, which return test data in about three weeks.

One molecule for a particular cancer, he said, “was generated completely without human intervention” and is “about two hundred times more potent than the competitor medicine that is available in the market”. Such work once took seven to eight years, he said; it now takes three to four months.

“But the back end, which is where we actually put these molecules into humans and test them against diseases, is still very much the same,” he said. “More medicines are emerging very rapidly from our engines, and then they’re getting blocked at the pinch point.” AI does not change what he called the “phase two coin flip”, the chance that a drug fails in mid-stage trials.

In a Q&A with HT’s R Sukumar, Mukherjee was asked whether medicine was “too hung up on the accepted model of clinical testing”, and if there is a case to radically overhaul that, given the computing power AI now offers. “Well, the quick answer is, yes, of course, there’s a radical way to change it,” Mukherjee said, but added that the question was whether it should be changed.

Medicine invented the randomised, blinded clinical trial “essentially to overcome human bias”, he said. “We want to see our medicine succeed.”

Trials could be sped up by using historical or simulated data as the comparison group, he said, but he warned of “BIBO, bias in, bias out”. Relying on such data alone, he said, risks “unleashing medicines into the world which actually don’t work or don’t work as well as we think they do”.

He suggested conditional approval, which he said the Europeans are trying “quite a lot”: a medicine is approved after a rapid trial, the trial continues with proper controls, and the approval can be withdrawn after two or three years.

He called India’s chance to change the economics of medicine the punchline of his talk. “Of all countries in the world, China and I truly believe India, with appropriate regulatory and technological reform,” can reverse a long trend in which, he said, the “number of medicines approved over time has actually been decreasing… and the cost of each medicine has been increasing”. “We have a historic opportunity in this country,” he said.

Source: https://www.hindustantimes.com/india-news/ai-speeding-up-drug-design-next-step-is-faster-cheaper-medicines-siddhartha-mukherjee-at-ht-leadership-summit-101794705620729.html

Previous Article
  • India

Jaishankar says India-US trade deal almost at finish line, remaining concerns more on American side

  • November 15, 2026
View Post
Next Article
  • India

Bihar flags 1.09 lakh mule accounts holding Rs 72.53 crore linked to fraud cases

  • November 15, 2026
View Post
You May Also Like
View Post
  • India

Sonam Wangchuk raises alarm over minor; Ladakh Police says boy, mother safe

  • November 15, 2026
View Post
  • India

‘Bharat Badnaam Summit’: BJP Attacks Rahul Gandhi Over Hyderabad Event, Accuses Him Of Defaming India

  • November 15, 2026
View Post
  • India

Delhi’s Air Quality Remains ‘Very Poor’ With AQI At 365, Multiple Areas Record Severe Pollution Levels

  • November 15, 2026
View Post
  • India

4 Pilgrims Dead, 18 Injured As Buses Trying To Avoid Errant Motorcyclist Collide In Punjab

  • November 15, 2026
View Post
  • India

Accused in Mad Sandhu’s murder held as police foil plot to shoot Bollywood actor

  • November 15, 2026
View Post
  • India

India votes to uphold Palestinian rights to land, water and energy at UN

  • November 15, 2026
View Post
  • India

Bihar flags 1.09 lakh mule accounts holding Rs 72.53 crore linked to fraud cases

  • November 15, 2026
View Post
  • India

Jaishankar says India-US trade deal almost at finish line, remaining concerns more on American side

  • November 15, 2026

Recent Posts

  • Sonam Wangchuk raises alarm over minor; Ladakh Police says boy, mother safe
  • 24 terrorists, 4 soldiers killed in separate clashes in Pakistan’s Khyber Pakhtunkhwa, Balochistan
  • ‘Bharat Badnaam Summit’: BJP Attacks Rahul Gandhi Over Hyderabad Event, Accuses Him Of Defaming India
  • Delhi’s Air Quality Remains ‘Very Poor’ With AQI At 365, Multiple Areas Record Severe Pollution Levels
  • Microsoft’s Global Meltdown: How India’s Govt Digital Backbone Stayed Up & Running
Categories
  • Auto (43)
  • Business (474)
  • Climate & Earth (16)
  • Coronavirus (17)
  • Crypto (26)
  • Entertainment (894)
  • Happiness Basket (7)
  • India (6,356)
  • Learn | Unlearn | Relearn (163)
  • Lifestyle (334)
  • Politics (98)
  • Research Discoveries (455)
  • Science & Technology (469)
  • Sports (1,054)
  • Trending (1,803)
  • Video (1)
  • World (10,300)
Read Selective

For Feedbacks, Advertisements or Any Other Concerns mail us at info@readselective.com

Pages
  • Home
  • About US
  • Contact Us
  • Privacy Policy
  • Terms of Use
Categories
  • Auto
  • Business
  • Climate & Earth
  • Coronavirus
  • Crypto
  • Entertainment
  • Happiness Basket
  • India
  • Learn | Unlearn | Relearn
  • Lifestyle
  • Politics
  • Research Discoveries
  • Science & Technology
  • Sports
  • Trending
  • Video
  • World
© 2024 Read Selective | Developed by SUGARA Technologies
  • Home
  • About US
  • Contact Us
  • Privacy Policy
  • Terms of Use

Input your search keywords and press Enter.

Go to mobile version